Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,520,564
  • Shares Outstanding, K 57,692
  • Annual Sales, $ 51,500 K
  • Annual Income, $ -197,610 K
  • 60-Month Beta 2.12
  • Price/Sales 47.91
  • Price/Cash Flow N/A
  • Price/Book 3.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -1.71
  • Number of Estimates 10
  • High Estimate -1.49
  • Low Estimate -1.97
  • Prior Year -1.74
  • Growth Rate Est. (year over year) +1.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.35 +6.14%
on 10/02/19
45.34 -3.20%
on 10/07/19
-0.33 (-0.75%)
since 09/17/19
3-Month
41.35 +6.14%
on 10/02/19
64.02 -31.44%
on 07/22/19
-15.54 (-26.15%)
since 07/17/19
52-Week
37.44 +17.23%
on 12/24/18
74.50 -41.09%
on 04/05/19
-22.15 (-33.54%)
since 10/17/18

Most Recent Stories

More News
Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA

Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.

BAYRY : 18.2800 (-0.08%)
INCY : 77.43 (-0.88%)
RARE : 43.89 (+0.46%)
RGNX : 39.03 (+1.67%)
Ultragenyx Announces FDA Accepts New Drug Application for UX007 (triheptanoin) for Treatment of Long-chain Fatty Acid Oxidation Disorders

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, today announced that the U.S. Food and...

RARE : 43.89 (+0.46%)
Ultragenyx Pharm Set to Possibly Pullback After Yesterday's Rally of 1.54%

Ultragenyx Pharm (NASDAQ:RARE) traded in a range yesterday that spanned from a low of $43.22 to a high of $44.47. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high...

RARE : 43.89 (+0.46%)
Ultragenyx Gets FDA Approval for Label Expansion of Crysvita

Ultragenyx (RARE) and partner Kyowa Kirin get FDA approval for the label expansion of Crysvita in pediatric patients with X-linked hypophosphatemia.

BAYRY : 18.2800 (-0.08%)
RARE : 43.89 (+0.46%)
RGNX : 39.03 (+1.67%)
ARCT : 10.25 (-5.18%)
Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis,...

RARE : 43.89 (+0.46%)
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approves Label Update for Crysvita(R) (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH)

Expanded Label Includes Additional Clinical Data Highlighting Superiority Over Conventional Therapy for Pediatric Patients and Extends Current U.S. Indication to Patients Aged Six Months and Older

RARE : 43.89 (+0.46%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Ardelyx Inc (ARDX , ADMS , RARE , MGNX , FLXN )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

ADMS : 4.00 (-0.50%)
ARDX : 4.63 (+6.68%)
RARE : 43.89 (+0.46%)
Shares of RARE Down 23.1% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Ultragenyx Pharm (NASDAQ:RARE) on July 9th, 2019 at $56.48. In approximately 2 months, Ultragenyx Pharm has returned 23.07% as of today's recent price of $43.45.

RARE : 43.89 (+0.46%)
After Yesterday's Decline of 2.06%, Ultragenyx Pharm Offers Investors Better Value

Ultragenyx Pharm (NASDAQ:RARE) traded in a range yesterday that spanned from a low of $43.31 to a high of $44.72. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of...

RARE : 43.89 (+0.46%)
20.9% Return Seen to Date on SmarTrend Ultragenyx Pharm Call (RARE)

SmarTrend identified a Downtrend for Ultragenyx Pharm (NASDAQ:RARE) on July 9th, 2019 at $56.48. In approximately 2 months, Ultragenyx Pharm has returned 20.87% as of today's recent price of $44.69.

RARE : 43.89 (+0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade RARE with:

Business Summary

Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023)...

See More

Key Turning Points

2nd Resistance Point 45.20
1st Resistance Point 44.54
Last Price 43.89
1st Support Level 43.29
2nd Support Level 42.70

See More

52-Week High 74.50
Fibonacci 61.8% 60.34
Fibonacci 50% 55.97
Fibonacci 38.2% 51.60
Last Price 43.89
52-Week Low 37.44

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar